Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTARES PHARMA, INC.

(ATRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ANTARES PHARMA, INC.
10/21Antares Pharma to Report Third Quarter 2021 Financial and Operating Results
GL
10/21ANTARES PHARMA : to Report Third Quarter 2021 Financial and Operating Results
GL
10/19ANTARES PHARMA : Enters into exclusive license agreement with lipocine for tlando in u.s.
AQ
10/19LIPOCINE : And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO
AQ
10/18LIPOCINE : Signs Deal with Antares Pharma for Commercialization of Tlando in the US; Share..
MT
10/18ANTARES PHARMA : Strikes Exclusive License Agreement For Oral Testosterone Replacement The..
MT
10/18ANTARES PHARMA : ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH LIPOCINE FOR TLANDO® IN U.S ..
PU
10/18ANTARES PHARMA : Enters into Exclusive License Agreement With Lipocine for TLANDO® in U.S.
GL
10/18Antares Pharma Enters into Exclusive License Agreement with Lipocine for Tlando® in U.S
CI
09/30ANTARES PHARMA : Starts Phase 1 Study of ATRS-1902 Drug for Acute Adrenal Insufficiency Tr..
MT
09/30ANTARES PHARMA : Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
AQ
09/30Antares Pharma, Inc. Initiates Phase I Study for ATRS-1902 for Adrenal Crisis Rescue
CI
09/08ANTARES PHARMA : to Participate in the H.C. Wainright 23rd Annual Global Investment Confer..
PU
09/08Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conf..
GL
08/06Antares pharma reports second quarter 2021 financial and operating resultsewing
AQ
08/05Antares Pharma, Inc. Reaffirms Revenue Guidance for the Full Year 2021
CI
08/05ANTARES PHARMA : Q2 Earnings Snapshot
AQ
08/05ANTARES PHARMA : Earnings Flash (ATRS) ANTARES PHARMA Reports Q2 Revenue $45M, vs. Street ..
MT
08/05ANTARES PHARMA : Earnings Flash (ATRS) ANTARES PHARMA Posts Q2 EPS $0.03, vs. Street Est o..
MT
08/05ANTARES PHARMA : Reports Second Quarter 2021 Financial and Operating Results
AQ
08/05Antares Pharma, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 202..
CI
07/28Antares Pharma to Report Second Quarter 2021 Financial and Operating Results
GL
07/22ANTARES PHARMA : Gets US FDA OK to Start Trial of ATRS-1902 in Acute Adrenal Insufficiency
MT
07/22ANTARES PHARMA : Announces FDA Acceptance of IND Application for ATRS 1902 For Adrenal Cri..
PU
07/22Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Cr..
GL
07/22Antares Pharma, Inc Announces FDA Acceptance of IND Application for ATRS-1902 for Adren..
CI
07/16ANTARES PHARMA : Truist Securities Initiates Coverage on Antares Pharma With Buy Rating, $..
MT
07/09INSIDER TRENDS : Insider Disposition Eases Back 90-Day Buy Trend at Antares Pharma
MT
07/07Antares Pharma to Present at the Ladenburg Thalmann Annual Healthcare Conference
GL
06/28ANTARES PHARMA : ' Swiss Partner Idorsia Kicks Off Late-Stage Study for Selatogrel in Hear..
MT
06/28Antares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Selatogrel fo..
GL
06/28Idorsia to trial self-injection drug for heart attack victims
RE
06/28PRESS RELEASE : Idorsia initiates the Phase 3 -2-
DJ
06/28PRESS RELEASE : Idorsia initiates the Phase 3 registration study with selatogrel for the t..
DJ
06/25ANTARES PHARMA, INC.(NASDAQCM : ATRS) added to Russell 2000 Growth-Defensive Index
CI
06/25ANTARES PHARMA, INC.(NASDAQCM : ATRS) added to Russell 2000 Defensive Index
CI
06/22ANTARES PHARMA : Files Investigational New Drug Application With FDA for Early Stage Study..
MT
06/22Antares Pharma Announces Submission of IND Application for ATRS-1902 for Adrenal Crisis..
GL
06/22Antares Pharma Announces Submission of IND Application for ATRS-1902 for Adrenal Crisis..
CI
06/21ANTARES PHARMA, INC.(NASDAQCM : ATRS) dropped from S&P Healthcare Equipment Select Industr..
CI
06/21ANTARES PHARMA, INC.(NASDAQCM : ATRS) added to S&P Pharmaceuticals Select Industry Index
CI
06/15Antares Pharma to Present at the Raymond James Human Health Innovations Conference
GL
06/14INSIDER TRENDS : Antares Pharma Insider Gets Stock Award, Buy Trend Intact
MT
06/14INSIDER TRENDS : Insider at Antares Pharma Receives Stock Award Uses Portion to Pay Taxes,..
MT
06/14INSIDER TRENDS : Antares Pharma Insider Granted Stock Award, Extends Buy Trend
MT
06/14INSIDER TRENDS : Antares Pharma Insider Receives Stock Award, Buy Trend Intact
MT
06/14INSIDER TRENDS : Antares Pharma Insider Receives Stock Award, Trend of Buys Extended
MT
06/14INSIDER TRENDS : Insider at Antares Pharma Receives Stock Award Uses Portion to Pay Taxes,..
MT
06/14INSIDER TRENDS : Antares Pharma Insider Gets Stock Award, Prolongs Buy Trend
MT
06/14INSIDER TRENDS : Antares Pharma Insider Receives Stock Award Uses Portion to Pay Taxes, Sl..
MT
06/10INSIDER TRENDS : Insider at Antares Pharma Disposes of Shares for Tax Slowing 90-Day Buy T..
MT
05/26Antares Pharma to Present at the Jefferies Virtual Healthcare Conference
GL
05/06ANTARES PHARMA : Q1 Earnings Snapshot
AQ
05/06Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial
GL
05/06ANTARES PHARMA : Earnings Flash (ATRS) ANTARES PHARMA Reports Q1 EPS $0.02, vs. Street Est..
MT
05/06ANTARES PHARMA : Earnings Flash (ATRS) ANTARES PHARMA Posts Q1 Revenue $42.1M, vs. Street ..
MT
05/06ANTARES PHARMA : Reports First Quarter 2021 Financial and Operating Results
AQ
05/06Antares Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 202..
CI
05/06Antares Pharma, Inc. Announces Executives Changes
CI
05/06Antares Pharma, Inc. Reaffirms Revenue Guidance for the Full Year of 2021
CI
05/03INSIDER TRENDS : Antares Pharma Insider Exercises Options Extending 90-Day Buying Trend
MT
05/03Antares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Vi..
GL
05/03Antares Pharma Announces Poster Presentation At the Pediatric Endocrine Society 2021 Vi..
CI
04/28Antares Pharma to Participate in the 7th Annual Truist Securities 2021 Life Sciences Su..
GL
04/27Antares Pharma to Report First Quarter 2021 Financial and Operating Results
GL
04/26Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and ..
GL
04/26Antares Pharma, Inc. Appoints Peter Richardson as Executive Vice President, Research an..
CI
03/02ANTARES PHARMA : Reports Higher Q4 Earnings, Revenue
MT
03/02ANTARES PHARMA : 4Q Earnings Snapshot
AQ
03/02ANTARES PHARMA : Earnings Flash (ATRS) ANTARES PHARMA Reports Q4 Revenue $44.1M, vs. Stree..
MT
03/02Antares Pharma Reports Fourth Quarter and Full-Year 2020 Financial and Operating Result..
GL
03/02Antares Pharma, Inc. Reaffirms Full-Year 2021 Revenue Guidance
CI
03/02Antares Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31,..
CI
02/24ANTARES PHARMA : to Present at Two Upcoming Investor Conferences
AQ
02/23ANTARES PHARMA : to Report Fourth Quarter and Full-Year 2020 Financial and Operating Resul..
AQ
1  2  3  4  5  6  7  8Next
Upcoming event on ANTARES PHARMA, INC.
11/09/21